The purpose of this study is to test a potential new treatment for a kidney condition called focal segmental glomerulosclerosis (FSGS). This condition is characterised by the development of scar tissue on the kidneys and is a serious condition that can lead to kidney failure and kidney transplants.

15 nights
2 prior to inpatient stay + 1 follow up visits

This medication has previously been tested in clinical studies of 90 healthy participants and was found to be well tolerated. In this study we are looking at how this medication interacts with common oral contraceptives – to make sure that when females take this new medication it does not have an impact on the effectiveness of their birth control. As part of this study you will be required to take both the study medication and the oral contraceptive pill.

The trial has been approved by an independent ethics committee and you will be reimbursed for your time.

Eligibility

Biological Sex Healthy females
Age 18 - 45 years old
BMI 18-32 kg/m²
Body Weight > 50kg
Medical History Nothing significant
Smoking History Non smokers (no smoking in past 90 days)
Contraception Either abstinent, in a same sex relationship, or if sexually active with a male partner using the non-hormonal IUD or are surgically sterile (hysterectomy or bilateral tubal occlusion)